Protocol for the development of a core domain set for hand eczema trials

被引:4
|
作者
Roensch, H. [1 ]
Apfelbacher, C. [2 ]
Brans, R. [3 ]
Ofenloch, R. [4 ]
Schuttelaar, M. L. A. [5 ]
Weisshaar, E. [4 ]
Bauer, A. [1 ]
机构
[1] Tech Univ, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[2] Otto von Guericke Univ, Med Fac, Inst Social Med & Hlth Syst Res, Magdeburg, Germany
[3] Univ Osnabruck, Inst Interdisciplinary Dermatol Prevent & Rehabil, Osnabruck, Germany
[4] Ruprecht Karls Univ Heidelberg, Dept Dermatol, Occupat Dermatol, Heidelberg, Germany
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Dermatol, Groningen, Netherlands
关键词
D O I
10.1111/jdv.16429
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Clinical hand eczema trials measure a variety of outcome domains to determine the success of interventions. This considerably limits the comparability and overall confidence in the study results, and thereby the strength of recommendations for clinical practice. Objectives The Hand Eczema Core Outcome Set (HECOS) initiative aims to develop a core outcome set (COS) for the standardized evaluation of interventions in future hand eczema trials and reviews. This COS will define the minimum that should be measured and reported in controlled and randomized-controlled trials of therapeutic hand eczema interventions. The objective of this protocol is to specify the methods to develop a core domain set. Methods In Phase 1, a list of candidate domains will be derived from a systematic literature review concerning previously measured outcomes in hand eczema trials, from qualitative patient interviews and from expert interviews. In Phase 2, a consensus study about core domains will be conducted by an online 3-round Delphi survey and a face-to-face meeting, applying predefined consensus criteria. HECOS involves hand eczema and methods experts as well as patients and further stakeholders with an interest in the initiative. Outlook When a set of core domains has been defined, HECOS is going to identify appropriate outcome measurement instruments in a development process that will be detailed in another protocol. The COS will considerably enhance the methodological quality, comparability and usefulness of hand eczema trials for clinical decision-making and the development of new therapeutic options for hand eczema, and also reduce the effort of planning, conducting, and reporting individual hand eczema studies, reviews and meta-analyses.
引用
收藏
页码:2871 / 2876
页数:6
相关论文
共 50 条
  • [1] Development of a Core-Outcome-Set for Studies on Hand Eczema
    Bauer, A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 11 - 11
  • [2] A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set
    Chiarotto, Alessandro
    Terwee, Caroline B.
    Deyo, Richard A.
    Boers, Maarten
    Lin, Chung-Wei Christine
    Buchbinder, Rachelle
    Corbin, Terry P.
    Costa, Leonardo O. P.
    Foster, Nadine E.
    Grotle, Margreth
    Koes, Bart W.
    Kovacs, Francisco M.
    Maher, Chris G.
    Pearson, Adam M.
    Peul, Wilco C.
    Schoene, Mark L.
    Turk, Dennis C.
    van Tulder, Maurits W.
    Ostelo, Raymond W.
    [J]. TRIALS, 2014, 15
  • [3] A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set
    Alessandro Chiarotto
    Caroline B Terwee
    Richard A Deyo
    Maarten Boers
    Chung-Wei Christine Lin
    Rachelle Buchbinder
    Terry P Corbin
    Leonardo OP Costa
    Nadine E Foster
    Margreth Grotle
    Bart W Koes
    Francisco M Kovacs
    Chris G Maher
    Adam M Pearson
    Wilco C Peul
    Mark L Schoene
    Dennis C Turk
    Maurits W van Tulder
    Raymond W Ostelo
    [J]. Trials, 15
  • [4] Protocol for development of a core outcome set for clinical trials in melasma
    Ibrahim, Sarah A.
    Kang, Bianca Y.
    Schlessinger, Daniel, I
    Chiren, Sarah G.
    Tang, Jennifer C.
    Kirkham, Jamie J.
    Schmitt, Jochen
    Poon, Emily
    Maher, Ian A.
    Sobanko, Joseph F.
    Cartee, Todd, V
    Alam, Murad
    [J]. BMJ OPEN, 2022, 12 (02):
  • [5] Core outcomes in periodontal trials: study protocol for core outcome set development
    Lamont, Thomas J.
    Clarkson, Jan E.
    Ricketts, David N. J.
    Heasman, Peter A.
    Ramsay, Craig R.
    [J]. TRIALS, 2017, 18
  • [6] Core outcomes in periodontal trials: study protocol for core outcome set development
    Thomas J. Lamont
    Jan E. Clarkson
    David N. J. Ricketts
    Peter A. Heasman
    Craig R. Ramsay
    [J]. Trials, 18
  • [7] Protocol for the development of a core domain set for individuals with ankle osteoarthritis
    Sultan Ayyadah Alanazi
    Bill Vicenzino
    Christiaan J. A. van Bergen
    David J. Hunter
    Erik A. Wikstrom
    Hylton B. Menz
    Yvonne M. Golightly
    Michelle D. Smith
    [J]. Trials, 23
  • [8] Protocol for the development of a core domain set for individuals with ankle osteoarthritis
    Alanazi, Sultan Ayyadah
    Vicenzino, Bill
    van Bergen, Christiaan J. A.
    Hunter, David J.
    Wikstrom, Erik A.
    Menz, Hylton B.
    Golightly, Yvonne M.
    Smith, Michelle D.
    [J]. TRIALS, 2022, 23 (01)
  • [9] Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials
    Kang, Bianca Y.
    Ibrahim, Sarah A.
    Shokeen, Divya
    Schlessinger, Daniel I.
    Kirkham, Jamie J.
    Schmitt, Jochen
    Poon, Emily
    Maher, Ian A.
    Sobanko, Joseph F.
    Cartee, Todd V.
    Alam, Murad
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2022, 314 (04) : 357 - 361
  • [10] Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials
    Bianca Y. Kang
    Sarah A. Ibrahim
    Divya Shokeen
    Daniel I. Schlessinger
    Jamie J. Kirkham
    Jochen Schmitt
    Emily Poon
    Ian A. Maher
    Joseph F. Sobanko
    Todd V. Cartee
    Murad Alam
    [J]. Archives of Dermatological Research, 2022, 314 : 357 - 361